Guide: A Basic Overview Of Serum Protein Manual Agarose Electrophoresis
June 25th, 2019
Study: Detection Of Benzodiazepines In Oral Fluid By Homogeneous Enzyme Immunoassay
June 20th, 2019
MEDICA 2019 - World Forum for Medicine
Düsseldorf, GermanyBooth No.: 3/D35-2
AACC Annual Scientific Meeting and Clinical Lab Expo
Anaheim Convention Center ~ Anaheim, CABooth No.: 2627
Thanks to Block Scientific, I was able to procure the re-certified Bayer DCA 2000+ without hassles and get the lab back in operation. The
device works perfectly and I look forward to doing more business with Block Scientific.
--- Mathew Anderson, New Jersey
The DRG DHEA ELISA is an enzyme immunoassay for the quantitative in vitro diagnostic measurement of Dehydroepiandrosterone (DHEA) in serum.
Dehydroepiandrosterone (DHEA; androstenolone; 3β-hydroxy-5-androsten-17-one) is a C19 steroid produced in the adrenal cortex and, to a lesser extent, gonads. DHEA serves as a precursor in testosterone and estrogen synthesis. Due to the presence of a 17-oxo (rather than hydroxyl) group, DHEA has relatively weak androgenic activity, which has been estimated at ~10% that of testosterone. However in neonates, peripubertal children and in adult women, circulating DHEA levels may be several-fold higher than testosterone concentrations, and rapid peripheral tissue conversion to more potent androgens (androstenedione and testosterone) and estrogens may occur. Moreover, DHEA has relatively low affinity for sex-hormone binding globulin.
These factors may enhance the physiologic biopotency of DHEA. The physiologic role of DHEA has not been conclusively defined. A variety of in vitro effects, including antiproliferative
effects in different cell lines and effects on enzyme-mediated cell metabolism, have been reported. In vivo studies suggest that DHEA may affect cholesterol and lipid metabolism, insulin sensitivity and secretion and immune function. Abnormal DHEA levels have been reported in schizophrenia and obesity. Therapeutic administration of DHEA has been proposed for several conditions, including obesity and cardiovascular disease.
Serum DHEA levels are relatively high in the fetus and neonate, low during childhood, and increase during puberty. Increased levels of DHEA during adrenarche may contribute to the development of secondary sexual hair. Serum DHEA levels progressively decline after the third decade of life. No consistent changes in serum DHEA levels occur during the menstrual cycle or pregnancy; however, parity may lower serum DHEA levels in premenopausal women.
DHEA has a rapid metabolic clearance rate as compared to its sulfated conjugate, DHEA-S. Because of this, serum DHEA levels are 100-1000 fold lower than DHEA-S levels. In addition, serum DHEA levels show significant diurnal variation which is dependent on adrenocorticotrophic hormone (ACTH). Serum DHEA levels increase in response to exogenous ACTH administration.
Measurement of serum DHEA is a useful marker of adrenal androgen synthesis. Abnormally low levels may occur in hypoadrenalism, and elevated levels occur in several conditions; including virilizing adrenal adenoma and carcinoma, 21-hydroxylase and 3β-hydroxysteroid dehydrogenase deficiencies and in some cases of female hirsutism. Since very little DHEA is produced by the gonads, measurement of DHEA levels may aid in the localization of androgen source in virilizing